2023-06-01 19:55:52
The United States approved a vaccine against the respiratory sinicidal virus (RSV) that causes bronchiolitis. This dose is for older than 60 years, who, along with children, are the most affected by this disease. Before your approval, the vaccine was tested on volunteers from Argentina and was highly effective.
The US regulatory agency, FDA, approved the Abrysvo vaccine developed by the Pfizer laboratory for people over 60 years of age and This is the second vaccine against RSV endorsed by the FDA in less than a month. The latter is significant since it is the first time in more than 50 years that an antidote for this disease has been achieved.
Pfizer’s RSV vaccine is based on protein subunit technology and, in authorizing it, the FDA took into account the results of the Phase III Renoir study with 37,000 participantswhich took place in Argentina, among other countries.
The volunteers from Argentina did it at the Central Military Hospital in Buenos Aires, where the company’s vaccine against SARS-CoV-2 had also been tested before.
The results are encouraging: overall efficacy is 66.7% and 85.7% against severe forms in older adults and there is good tolerance and no safety problems.
On May 3, the FDA had approved the world’s first vaccine against RSV. In this case it was the development of the British laboratory GSK and was 82.6% effective in preventing lower respiratory tract infections, the company reported in a post-approval statement.
Bronchiolitis and other respiratory diseases in children
Respiratory syncytial virus (RSV) It is one of the main causes of bronchiolitis in children. respiratory conditions were the ones that generated the most medical consultations so far this year In the case of minors, although the levels of contagion of these respiratory viruses, the authorities alert, circulate at the usual seasonal level that they had before the Covid-19 pandemic.
This virus attacks the respiratory system and it is particularly risky in cases of children under 2 years of age, as the bronchioles are still developing and can become inflamed, leading to bronchiolitis. In Argentina, respiratory conditions They are the third cause of mortality in children under 5 years of age.
Among the recommendations is the vaccination of boys and girls between 6 and 24 months of age. Although there are still no vaccines for some of the common respiratory viruses, many of the infections that are reported are also from the flu and can be prevented with proper vaccination.
Alert for bronchiolitis in children: a winter is expected with a “very important” level of cases
The flu vaccination campaign in order to reduce serious complications, hospitalizations and deaths related to this disease is aimed at health personnel, pregnant people (at any time during pregnancy), puerperal people (before discharge from the maternity hospital), girls and boys from 6 to 24 months of age, people from 2 to 64 years with risk factors, general population from 65 years.
The flu vaccine, available free of charge in all public vaccination centers and hospitals in the country, can be co-administered together with the other vaccines on the National Calendar and with the vaccine against COVID-19, details the official information.
LT.
You may also like
#United #States #approved #vaccine #bronchiolitis #virus #tested #volunteers #Argentina